| Schedule of financial information by reportable segment |
The following is financial information relating to the Company's reportable segments (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
Nine Months Ended |
|
|
March 31, |
|
March 31, |
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
Net sales: |
|
|
|
|
|
|
|
|
|
|
|
|
Protein Sciences |
|
$ |
214,589 |
|
$ |
218,903 |
|
$ |
616,914 |
|
$ |
622,739 |
Diagnostics and Genomics |
|
|
87,511 |
|
|
75,669 |
|
|
235,715 |
|
|
213,577 |
Other revenue(1) |
|
|
2,093 |
|
|
— |
|
|
2,093 |
|
|
— |
Intersegment |
|
|
(765) |
|
|
(426) |
|
|
(1,761) |
|
|
(934) |
Consolidated net sales |
|
$ |
303,428 |
|
$ |
294,146 |
|
$ |
852,961 |
|
$ |
835,382 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income: |
|
|
|
|
|
|
|
|
|
|
|
|
Protein Sciences |
|
$ |
94,829 |
|
$ |
98,756 |
|
$ |
262,777 |
|
$ |
274,035 |
Diagnostics and Genomics |
|
|
8,104 |
|
|
11,464 |
|
|
13,189 |
|
|
28,399 |
Segment operating income |
|
$ |
102,933 |
|
$ |
110,220 |
|
$ |
275,966 |
|
$ |
302,434 |
Costs recognized on sale of acquired inventory |
|
|
(186) |
|
|
— |
|
|
(550) |
|
|
(400) |
Amortization of intangibles |
|
|
(19,287) |
|
|
(19,286) |
|
|
(58,908) |
|
|
(57,694) |
Impact of partially-owned consolidated subsidiaries(2) |
|
|
— |
|
|
— |
|
|
— |
|
|
647 |
Acquisition related expenses and other |
|
|
(3,286) |
|
|
1,333 |
|
|
(2,173) |
|
|
9,343 |
Impairment of assets held-for-sale |
|
|
— |
|
|
— |
|
|
(6,038) |
|
|
— |
Stock based compensation, inclusive of employer taxes |
|
|
(8,358) |
|
|
(10,543) |
|
|
(32,810) |
|
|
(42,879) |
Restructuring and restructuring-related costs |
|
|
(1,550) |
|
|
— |
|
|
(7,157) |
|
|
(2,950) |
Corporate general, selling, and administrative expenses |
|
|
(3,346) |
|
|
(1,513) |
|
|
(7,545) |
|
|
(4,082) |
Impact of business held-for-sale(1) |
|
|
78 |
|
|
— |
|
|
78 |
|
|
— |
Consolidated operating income |
|
$ |
66,998 |
|
$ |
80,211 |
|
$ |
160,863 |
|
$ |
204,419 |
(1) Includes the quarterly results of a business that has met the held-for-sale criteria since December 31, 2023.
(2) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023.
|